All In Biotech

Drug Trial Radar · NCT00980109

Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir

A Phase IV, Multi-center, Randomized, Partially Double Blinded, Placebo Controlled Study, to Evaluate the Safety of Daily Inhaled Zanamivir 10 mg Versus Placebo and Daily Oral Oseltamivir 75 mg Versus Placebo for Influenza Prophylaxis in Healthy Volunteers for 16 Weeks

Last checked: Nov 20, 2026Latest source record: Sep 22, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

390

Actual

Start

Sep 2009

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Sep 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 20 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, randomised, four arms placebo controlled study to evaluate the safety and tolerability of 10 mg inhaled zanamivir once a day and 75 mg oseltamivir capsule orally once a day relative to placebo over 16 weeks (112 days). Enrolled subjects will be randomly assigned to 2:1:2:1 ratio (active oseltamivir: placebo: active zanamivir: placebo) on one of the four study treatment groups. It is hypothesized that oseltamivir and zanamivir will protect participants from becoming infected with influenza.

Conditions

  • Influenza

Interventions

  • active oseltamivirDrug

    Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.

  • placebo capsuleDrug

    Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.

  • zanamivir for inhalationDrug

    Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.

  • placebo for inhalationDrug

    Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who withdraw from the study because of serious adverse events (SAEs) that are possibly or probably or definitely related to the study drugTime frame: 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital for Tropical Diseases

    Bangkok, Thailand

  • Faculty of Medicine Siriraj Hospital

    Bangkok, Bangkoknoi, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.